Prescription medicine

Betamethasone and calcipotriene Brand names: Enstilar, Taclonex, Wynzora, Attero

Betamethasone and calcipotriene (Taclonex) is a prescription medicine with an FDA approval on record since 2006. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $1.81 per gram (Calcipotriene-betamethasone dp 0.005%-0.064% ointment) in the October 7, 2026 NADAC survey.

Generic listed

Check it at the source: the betamethasone and calcipotriene FDA label on DailyMed (effective December 12, 2022, Prasco Laboratories); the NDA 21852 record on Drugs@FDA; every betamethasone and calcipotriene label on DailyMed.

Highlights of the record

FDA label of December 12, 2022; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026

Used for

From the label: indications and usage
Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

Forms and strengths

0.05 mg/g / 0.5 mg/g
0.5 mg/g
0.643 mg/g
50 mg/g
64 mg/g

Ointment; suspension; aerosol (foam); solution; cream.

On the market

Earliest approval on file: January 9, 2006 Taclonex, Leo Pharma As; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: 6 first January 14, 2013; 3 with a marketed status in Drugs@FDA
Labelers listed (NDC): 8 of which 5 under generic applications, 2 under brand applications, repackagers included
Last listed patent: March 18, 2039 Wynzora cream; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): $1.81 per gram Calcipotriene-betamethasone dp 0.005%-0.064% ointment
Shortage (FDA): No current entry
Recalls by its makers (FDA): 1 since 2017 0 Class I among all firms' recalls; latest January 16, 2017
FAERS reports: 3,232 through July 30, 2026

What is betamethasone and calcipotriene used for?

From the label: indications and usage
Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

Conditions named in the indications of betamethasone and calcipotriene's FDA labels, with every medicine labeled for each:

Psoriasis

FDA pharmacologic class: Corticosteroid and Vitamin D Analog.

Source: FDA drug label (Calcipotriene and Betamethasone Dipropionate), NDA021852 (Leo Pharma As), as published by Prasco Laboratories, effective December 12, 2022 (SPL set d9493e66-251c-426c-90a8-1bf1e526ab85), via openFDA; the full label on DailyMed

What does the patient leaflet for betamethasone and calcipotriene say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What should I avoid while using Calcipotriene and Betamethasone Dipropionate Ointment?
Avoid spending a long time in the sunlight. Avoid tanning booths and sunlamps. Use sunscreen if you have to be in the sunlight. Talk to your doctor if you get a sunburn.

From the patient leaflet: How should I store Calcipotriene and Betamethasone Dipropionate Ointment?
Store Calcipotriene and Betamethasone Dipropionate Ointment at room temperature, 68°F - 77°F (20°C - 25°C); Make sure the cap on the tube is tightly closed. Calcipotriene and Betamethasone Dipropionate Ointment has an expiration date (exp.) marked on the tube. Do not use the ointment after this date. Keep Calcipotriene and Betamethasone Dipropionate Ointment and all medicines out of the reach of children and pets.

Is there a generic for betamethasone and calcipotriene (Taclonex)?

The FDA approved the first generic betamethasone and calcipotriene on January 14, 2013. 6 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

FDA's NDC Directory lists betamethasone and calcipotriene from 5 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

The Orange Book lists no patent for Taclonex ointment; a patent listed only for Wynzora cream runs to March 18, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2006 earliest approval on file
2013 first generic approved
2039 last listed patent
red ticks recalls

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do pharmacies pay for betamethasone and calcipotriene (Taclonex)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.81 per gram (Calcipotriene-betamethasone dp 0.005%-0.064% ointment), down 15% from $2.14 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Calcipotriene-betamethasone dp 0.005%-0.064% suspension (generic)
Taclonex 0.005%-0.064% suspension (brand)

$20.80

$1.10

January 2024October 2026

NADAC per unit, October 7, 2026
Strength and form	Brand or generic	Pharmacy cost	30 tablets, or one pen or vial	12-month change
Calcipotriene-betamethasone dp 0.005%-0.064% ointment	Generic	$1.81 per gram	n/a	-15%
Calcipotriene-betamethasone dp 0.005%-0.064% suspension	Generic	$1.32 per gram	n/a	-8%
Enstilar 0.005%-0.064% foam	Brand	$21.84 per gram	n/a	+0.1%
Taclonex 0.005%-0.064% suspension	Brand	$20.70 per gram	n/a	+0.1%

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

Has betamethasone and calcipotriene been recalled?

The FDA's Enforcement Report lists 1 recall naming betamethasone and calcipotriene since 2017: 0 Class I (the most serious), 0 Class II, 1 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.

Started	Class	Company	Reason
January 16, 2017	Class III	LEO PHARMA INC	Labeling: Incorrect or missing package insert: the affected product was packaged with an out-of-date package insert (PI) dated February 2014.

Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026

What does the betamethasone and calcipotriene label say about other medicines?

The betamethasone and calcipotriene label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Clobetasol	warnings and precautions	Glaucoma and cataracts have been reported in postmarketing experience with the use of topical corticosteroid products, including topical clobetasol products.
Cosyntropin	warnings and precautions	Evaluation for HPA axis suppression may be done by using the cosyntropin stimulation test [see Clinical Pharmacology (12.2) ].

Check betamethasone and calcipotriene against other medicines

What do FAERS reports show for betamethasone and calcipotriene?

The FDA Adverse Event Reporting System holds 3,232 reports that list betamethasone and calcipotriene among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 115 are coded as a death and 760 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

Psoriasis (a use or a product term, not a reaction)644
Drug Ineffective (a use or a product term, not a reaction)300
Diarrhoea224
Headache (named in the label)196
Pruritus (named in the label)177
Nausea172
Pain150
Arthralgia141

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as betamethasone and calcipotriene?

9 other medicines are given the same way (topical) and in the same FDA class as betamethasone and calcipotriene or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (topical)	Pharmacy cost	Shortage
Clobetasol	Psoriasis	40 labelers	$0.126 per gram 0.05% ointment	No current entry
Fluocinolone	Psoriasis	15 labelers	$0.171 per mL 0.01% scalp oil	No current entry
Desoximetasone	Psoriasis	13 labelers	$0.369 per gram 0.25% ointment	No current entry
Halobetasol	Psoriasis	6 labelers	$0.620 per gram 0.05% ointmnt	No current entry
Halobetasol and tazarotene	Psoriasis	none listed	n/a	No current entry
Coal tar	Psoriasis	none listed	$0.0088 per mL 0.5% shampoo	No current entry
Tazarotene	Psoriasis	6 labelers	$6.11 per gram 0.1% gel	No current entry
Calcitriol	Psoriasis	none listed	n/a	A presentation being discontinued

Every medicine labeled for the same conditions as betamethasone and calcipotriene

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to betamethasone and calcipotriene: 9 medicines for the same use
Other corticosteroids: the pharmacologic class, with prices and generics
Betamethasone and calcipotriene side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other